RT Journal Article
SR Electronic
T1 Biochemical Recurrence of Prostate Cancer: Initial Results with [<sup>18</sup>F]PSMA-1007 PET/CT
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 632
OP 635
DO 10.2967/jnumed.117.196329
VO 59
IS 4
A1 Giesel, Frederik L.
A1 Will, Leon
A1 Kesch, Claudia
A1 Freitag, Martin
A1 Kremer, Christophe
A1 Merkle, Jonas
A1 Neels, Oliver C.
A1 Cardinale, Jens
A1 Hadaschik, Boris
A1 Hohenfellner, Markus
A1 Kopka, Klaus
A1 Haberkorn, Uwe
A1 Kratochwil, Clemens
YR 2018
UL http://jnm.snmjournals.org/content/59/4/632.abstract
AB Biochemical recurrence (BCR) is a concern for prostate cancer patients after local treatment. 68Ga-labeled prostate-specific membrane antigen (PSMA) ligands have significantly improved prostate cancer imaging. However, several 18F-labeled ligands that were developed as fluorinated tracers might present advantages. In this study, we analyzed the potential of 18F-PSMA-1007 in patients with BCR. Methods: Twelve patients with BCR after local treatment underwent PET/CT scans 1 and 3 h after injection of 18F-PSMA-1007. Results: 18F-PSMA-1007 PET/CT detected lesions in 9 of 12 patients (75%). A significant difference was observed when comparing the tracer uptake in 18F-PSMA-1007–positive lesions 1 and 3 h after injection (median SUVmax, 7.00 vs. 11.34; P &lt; 0.001; n = 76). Forty-four (88%) of 50 18F-PSMA-1007–positive lymph nodes had a short-axis diameter of less than 8 mm. Conclusion: In this pilot study, 18F-PSMA-1007 PET/CT presented high potential for localization of recurrent disease in prostate cancer patients with BCR.